EUVIMEDSkopri EUVIMED
Crossref

Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab

Toshinori Toyota, Satoshi Narahara iD, Haruki Uojima, Yuki Kitano iD, Takahiro Mizuta, Daiki Maeda, Soutarou Kurano, Kentaro Tanaka, Hiroki Inada iD, Munenori Honda iD, Yoko Yoshimaru, Takehisa Watanabe iD and 14 more

Hepatology Research · 2026-11 · 56 (11) · 1596-1605

DOI: 10.1111/hepr.70232 ↗

At a glance

Journal article in Hepatology Research, published online on 2026-07-06. Written by Toshinori Toyota and 25 co-authors. Institution: Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan. 28 references. Funded by: Japan Agency for Medical Research and Development.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aim

Statins contribute to the preservation of hepatic function and reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic liver disease; however, their clinical significance during systemic therapy for unresectable HCC remains unclear. Therefore, we investigated whether baseline statin use influences clinical outcomes in patients with unresectable HCC treated with atezolizumab plus bevacizumab.

Methods

We conducted a multicenter, retrospective cohort study of patients with unresectable HCC treated with atezolizumab–bevacizumab. Patients were classified as statin users or non‐users at treatment initiation. The primary outcome was overall survival (OS), and secondary outcomes included progression‐free survival (PFS) and post‐progression survival (PPS). To adjust for baseline imbalances, inverse probability of treatment weighting (IPTW) was applied, and propensity score (PS) matching was performed as a sensitivity analysis.

Results

A total of 284 patients were included, of whom 50 received statins. In the unadjusted cohort, OS was significantly longer in statin users than in non‐users ( p = 0.026). After IPTW adjustment, this OS benefit remained significant ( p = 0.031). In contrast, PFS did not differ significantly between groups in either the unadjusted ( p = 0.291) or IPTW‐adjusted cohorts ( p = 0.117). PPS was significantly prolonged in the statin group ( p = 0.006), with consistent findings after IPTW adjustment ( p = 0.018). In addition, deterioration in ALBI score was attenuated in statin users, suggesting better preservation of hepatic functional reserve.

Conclusions

Statin use was associated with significantly improved OS and PPS without affecting PFS, likely reflecting host‐related benefits through preservation of hepatic function.

Subjects

Author keywords

atezolizumab–bevacizumabhepatocellular carcinomaliver functionoverall survivalstatins

Authors and institutions

  • Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan.
  • Department of Gastroenterological Surgery, Kumamoto University, Chuo-ku, Kumamoto, Japan.
  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
  • Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, Chuo-ku, Kumamoto, Japan.
  • Department of Gastroenterology, Amakusa Medical Center, Amakusa, Japan.

ORCID profiles: Satoshi Narahara, Yuki Kitano, Hiroki Inada, Munenori Honda, Takehisa Watanabe, Hiroko Setoyama, Hisashi Hidaka, Yasuhito Tanaka

Funding

  • Japan Agency for Medical Research and Development

Cite

APA

Toyota, T., Narahara, S., Uojima, H., Kitano, Y., Mizuta, T., Maeda, D., Kurano, S., Tanaka, K., Inada, H., Honda, M., Yoshimaru, Y., Watanabe, T., Nagaoka, K., Setoyama, H., Hayashi, H., Suzuki, T., Matsuura, K., Iwasaki, S., Nomura, N., …, & Tanaka, Y. (2026). Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab. Hepatology Research, 56(11), 1596-1605. https://doi.org/10.1111/hepr.70232

Vancouver

Toyota T, Narahara S, Uojima H, Kitano Y, Mizuta T, Maeda D, et al. Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab. Hepatology Research. 2026;56(11):1596-1605. doi:10.1111/hepr.70232

BibTeX
@article{Toyota2026,
  author = {Toyota, Toshinori and Narahara, Satoshi and Uojima, Haruki and Kitano, Yuki and Mizuta, Takahiro and Maeda, Daiki and Kurano, Soutarou and Tanaka, Kentaro and Inada, Hiroki and Honda, Munenori and Yoshimaru, Yoko and Watanabe, Takehisa and Nagaoka, Katsuya and Setoyama, Hiroko and Hayashi, Hiromitsu and Suzuki, Takanori and Matsuura, Kentaro and Iwasaki, Shuichiro and Nomura, Nao and Miyase, Shiho and Yuruki, Hideto and Sakai, Yoshinari and Kudo, Koichi and Hidaka, Hisashi and Iwatsuki, Masaaki and Tanaka, Yasuhito},
  title = {Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {11},
  pages = {1596--1605},
  doi = {10.1111/hepr.70232}
}
Start for free →